APA (7th ed.) Citation

Gagne, M., Flynn, B. J., Honeycutt, C. C., Flebbe, D. R., Andrew, S. F., Provost, S. J., . . . Douek, D. C. (2024). Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways. Nature communications, 15(1), 6894-13. https://doi.org/10.1038/s41467-024-51046-w

Chicago Style (17th ed.) Citation

Gagne, Matthew, et al. "Variant-proof High Affinity ACE2 Antagonist Limits SARS-CoV-2 Replication in Upper and Lower Airways." Nature Communications 15, no. 1 (2024): 6894-13. https://doi.org/10.1038/s41467-024-51046-w.

MLA (9th ed.) Citation

Gagne, Matthew, et al. "Variant-proof High Affinity ACE2 Antagonist Limits SARS-CoV-2 Replication in Upper and Lower Airways." Nature Communications, vol. 15, no. 1, 2024, pp. 6894-13, https://doi.org/10.1038/s41467-024-51046-w.